For patients with JPS polyps, our study identifies several potential approaches, including anti‐TNF, anti‐CD44 and anti‐VEGF therapies, to reduce polyp recurrence after polypectomy or serve as palliative treatments if polypectomy is not feasible. The gene discussed is TNF; the disease is juvenile polyposis syndrome.